Skip to content
NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

Integer Holdings Corp. ITGR

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.9B
▲ 8.0% YoY
$102.8M
▼ 14.3% YoY
$105.1M
▲ 5.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Integer Holdings Corporation, headquartered in Plano, Texas, is a medical device contract development and manufacturing organization serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. It operates its business in one reportable segment and derives its revenue from three principal product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. In 2025, approximately 53% of the company's products sold were shipped to locations in the United States. During 2025, three of its customers, Abbott Laboratories, Boston Scientific and Medtronic, were each in excess of 10% of total sales and collectively accounted for 49% of total sales. As of December 31, 2025, Integer employed approximately 11,000 associates, in addition to a contingent workforce of approximately 400. As of December 31, 2025, its workforce was distributed 43% in the United States, 25% in Mexico and 15% in Ireland.

Written from the business description in Integer Holdings Corporation's annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.9B
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.9 · Net income 0.1
1B2B
2009201220152018202120242025
Compound annual growth
+11.7%
+11.5%
+8.8%
+8.7%
+15.7%
+5.9%
+7.8%
+13.2%
+4.4%
+5.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.5% a year over the five years to FY2025 — but profit grew slower: net income at +5.9%, earnings per share at +4.4%.

The share count rose from 0.03B to 0.03B over the period.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

6 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 11.9% · Net 5.5%
5.0%10.0%-0.5%-1.0%-1.5%
200920172025
ROE
FY2025 · ROE 6.1%
5%10%15%-1%-2%
200920172025
Three returns, three denominators.

Each USD of equity produced 6 cents of profit this year.

Cash & shareholders

USD 46.4M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 105.1
50M100M-15M-30M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 46.4
20M40M
202320242025

USD 46.4M in buybacks — 45% of the year's profit went back to shareholders.

Total assetsUSD 3.4B
EquityUSD 1.7B
CashUSD 17.2M
Gross debtUSD 1.2B
Net debtUSD 1.2B
Current ratio3.32×

Net debt stands at 67% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ITGR, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B1.91.71.61.31.21.11.31.21.11.10.80.70.70.60.60.50.5
Operating income $B0.20.20.20.10.10.10.20.20.10.10.00.10.10.00.10.10.0
EBITDA $B0.40.30.30.20.20.20.20.20.20.20.10.10.10.10.10.10.0
Income tax $B0.00.00.00.00.00.00.00.0−0.00.0−0.00.00.00.00.00.0−0.0
Net income $B0.10.10.10.10.10.10.10.20.10.0−0.00.10.0−0.00.00.0−0.0
Free cash flow $B0.10.10.10.00.10.10.10.10.10.0−0.00.10.00.00.10.10.1
EPS, diluted $2.893.362.691.992.912.332.925.152.080.19−0.292.141.43−0.201.401.40−0.39
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %6.17.66.24.87.46.48.717.28.20.8−1.09.67.1−1.07.48.2−2.4
Shares out B0.030.030.030.030.030.030.030.030.030.030.030.030.020.020.020.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image